Mekinist (trametinib) 2 mg film-coated tablets, 30 tablets — generic (Bangladesh) Targeted cancer therapy. Drug delivery from Europe within 4-5 days, guaranteed storage conditions, payment upon receipt. Order by calling +380996042415, Viber, or WhatsApp.

Indications

Trametinib is indicated as monotherapy for the treatment of patients with unresectable or metastatic melanoma harboring the BRAF V600e or V600k gene mutations who have not previously received BRAF inhibitor therapy.6,8

It is used in combination with dabrafenib for:

the treatment of unresectable or metastatic melanoma harboring the BRAF V600E or V600K gene mutations.7

the adjuvant treatment of patients with melanoma harboring the BRAF V600E or V600K gene mutations and node-positive disease after complete resection.7,8

the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with the BRAF V600E mutation.7 In Europe, it is indicated for the treatment of adult patients with advanced non-small cell lung cancer with the BRAF V600 mutation.8

Treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with the BRAF V600E mutation and no satisfactory locoregional treatment options.7

Treatment of adults and children aged six years and older with unresectable or metastatic solid tumors with the BRAF V600E mutation who have experienced disease progression after prior treatment and no satisfactory alternative treatment options. In the US, this indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent on confirmation and description of clinical benefit in confirmatory study(s).7

Treatment of pediatric patients one year of age and older with BRAF V600E-mutated low-grade glioma (LGG) who require systemic therapy.7